SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action
The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Abstract
There is compelling evidence that sodium–glucose cotransporter 2 (SGLT2) inhibitors exert cardioprotective and renoprotective effects that are far greater than expected based on their effects on glycemia or glycosuria. In large-scale randomized controlled trials, SGLT2 inhibitors reduce the risk of hospitalizations for heart failure by ∼30% and often decrease the risk of cardiovascular death (1). This benefit is particularly striking in patients who have the most marked impairment of systolic function prior to treatment. In parallel, SGLT2 inhibitors also reduce the risk of end-stage renal events, including the occurrence of renal death and the need for dialysis or renal transplantation by ∼30% (2). This benefit is seen even when glomerular filtration rates are sufficiently low to abolish the glycosuric effect of these drugs. These cardiorenal benefits cannot be explained by an action of SGLT2 inhibitors to lower blood glucose, since similar effects are not seen with antidiabetes drugs that have greater antihyperglycemic actions. Additionally, they cannot be ascribed to a natriuretic action, since these drugs exert only a modest effect on plasma volume or on circulating natriuretic peptides (3). In 2016, two articles published in Diabetes Care proposed the “thrifty fuel hypothesis” to explain the cardiorenal benefits of SGLT2 inhibitors. Ferrannini et al. (4) and Mudaliar et al. (5) postulated that the action of SGLT2 inhibitors to promote ketogenesis might account for their favorable effects on the heart and kidney because enhanced ketone bodies formation might possibly provide an efficient fuel that could boost the energy state of organs under stress. However, type 2 diabetes represents a state of nutrient overabundance and not energy deprivation, as is evidenced by the enhancement of molecular pathways that promote both energy retention (e.g., through SGLT2 upregulation) and energy storage (6,7). In fact, the stressed heart already preferentially utilizes ketone bodies, …
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, according to Packer M, SGLT2 inhibitors cause transcriptional changes in cells that occur during starvation, which is called “state of fasting mimicry” and include SIRT/AMPK activation and Akt/mTOR suppression (Figure 3).”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [106]
In the citing paper
“Moreover, taking flozins causes changes similar to an ischemic state, including HIF-2α activation which stimulates erythropoiesis, and patients with higher erythrocyte count benefited most from SGLT2i therapy.”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [106]
Citations
Cites
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux
Samuel, V. T., & Shulman, G. I. (2016) · Journal of Clinical Investigation · doi:10.1172/jci77812 · Cited by 1,484
Sirt1 Regulates Aging and Resistance to Oxidative Stress in the Heart
Alcendor, R. R., Gao, S., Zhai, P., Zablocki, D., Holle, E., Yu, X., Tian, B., Wagner, T., Vatner, S. F., & Sadoshima, J. (2007) · Circulation Research · doi:10.1161/01.res.0000267723.65696.4a · Cited by 1,147
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Neuen, B. L., Young, T., Heerspink, H. J. L., Neal, B., Perkovic, V., Billot, L., Mahaffey, K. W., Charytan, D. M., Wheeler, D. C., Arnott, C., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30256-6 · Cited by 893
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740 · cited 1×
“Such a relationship may explainwhy, in statisticalmediation analyses, erythrocytosis has been the most powerful predictor of the action of SGLT2 inhibitors to reduce heart failure events in large-scale trials (44,45).”
BackgroundThe Failing Heart Relies on Ketone Bodies as a Fuel
Aubert, G., Martin, O. J., Horton, J. L., Lai, L., Vega, R. B., Leone, T. C., Koves, T., Gardell, S. J., Krüger, M., Hoppel, C. L., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017355 · Cited by 707
Mudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571
Zhou, H., Wang, S., Zhu, P., Hu, S., Chen, Y., & Ren, J. (2018) · Redox Biology · doi:10.1016/j.redox.2017.12.019 · Cited by 550
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
Rådholm, K., Figtree, G., Perkovic, V., Solomon, S. D., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Barrett, T. D., Shaw, W., Desai, M., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034222 · Cited by 488
Research works printed but not linked: 1
- Balaiya, 2012, Hypoxia initiates sirtuin1-mediated vascular endothelial growth factor activation in choroidal endothelial cells through hypoxia inducible factor-2α, Mol Vis, 18, 114
Cited by
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Sotagliflozin in patients with diabetes and chronic kidney disease
Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030186 · Cited by 1,205
NAFLD and cardiovascular diseases: a clinical review
Kasper, P., Martin, A., Lang, S., Kütting, F., Goeser, T., Demir, M., & Steffen, H.-M. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01709-7 · Cited by 632
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 516
“An emerging theory links this to autophagy stimulation, including in the kidney and heart (20, 70, 97) (Figures 1 and 3).”
BackgroundQuagliariello, V., De Laurentiis, M., Rea, D., Barbieri, A., Monti, M. G., Carbone, A., Paccone, A., Altucci, L., Conte, M., Canale, M. L., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01346-y · Cited by 367
Anker, S. D., Butler, J., Filippatos, G., Khan, M. S., Marx, N., Lam, C. S. P., Schnaidt, S., Ofstad, A. P., Brueckmann, M., Jamal, W., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051824 · Cited by 352
Self-citationNeuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
Nassif, M. E., Qintar, M., Windsor, S. L., Jermyn, R., Shavelle, D. M., Tang, F., Lamba, S., Bhatt, K., Brush, J., Civitello, A., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.052503 · Cited by 281
Mapping the single-cell transcriptomic response of murine diabetic kidney disease to therapies
Wu, H., Gonzalez Villalobos, R., Yao, X., Reilly, D., Chen, T., Rankin, M., Myshkin, E., Breyer, M. D., & Humphreys, B. D. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.05.010 · Cited by 243
Jiang, K., Xu, Y., Wang, D., Chen, F., Tu, Z., Qian, J., Xu, S., Xu, Y., Hwa, J., Li, J., et al. (2022) · Protein & Cell · doi:10.1007/s13238-020-00809-4 · Cited by 187
SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism
Packer, M. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00824-4 · Cited by 185
Self-citationThe Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction
Packer, M. (2025) · JACC · doi:10.1016/j.jacc.2025.06.055 · Cited by 173
Self-citationAutophagy in the diabetic heart: A potential pharmacotherapeutic target in diabetic cardiomyopathy
Dewanjee, S., Vallamkondu, J., Kalra, R. S., John, A., Reddy, P. H., & Kandimalla, R. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101338 · Cited by 174
Euglycemic diabetic ketoacidosis: A missed diagnosis
Nasa, P., Chaudhary, S., Shrivastava, P. K., & Singh, A. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i5.514 · Cited by 164
Current and future therapies for type 1 diabetes
von Scholten, B. J., Kreiner, F. F., Gough, S. C. L., & von Herrath, M. (2021) · Diabetologia · doi:10.1007/s00125-021-05398-3 · Cited by 173
Critical Role for AMPK in Metabolic Disease-Induced Chronic Kidney Disease
Juszczak, F., Caron, N., Mathew, A. V., & Declèves, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217994 · Cited by 157
“Although the AMPK regulation of SGLT2 has not been clearly addressed, the use of SGLT2 inhibitors mimics the cellular response to starvation and indirectly activates AMPK, leading to the improvement of nephropathy development [106].”
BackgroundEmergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
Tsai, K., Chen, Y., Chiou, T. T., Chu, T., Li, L., Ng, H., Lee, W., & Lee, C. (2021) · Antioxidants · doi:10.3390/antiox10081166 · Cited by 149
SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback
Upadhyay, A. (2024) · Kidney360 · doi:10.34067/kid.0000000000000425 · Cited by 167
Packer, M. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.05.019 · Cited by 131
Self-citationHoong, C. W. S., & Chua, M. W. J. (2021) · Endocrinology · doi:10.1210/endocr/bqab079 · Cited by 110
State-of-the-Art-Review: Mechanisms of Action of SGLT2 Inhibitors and Clinical Implications
Vallon, V. (2024) · American Journal of Hypertension · doi:10.1093/ajh/hpae092 · Cited by 140
Mutual Antagonism of Hypoxia-Inducible Factor Isoforms in Cardiac, Vascular, and Renal Disorders
Packer, M. (2020) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.05.006 · Cited by 107
Self-citationTromp, J., Ponikowski, P., Salsali, A., Angermann, C. E., Biegus, J., Blatchford, J., Collins, S. P., Ferreira, J. P., Grauer, C., Kosiborod, M., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2137 · Cited by 99
Packer, M. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad235 · Cited by 107
“83”
Self-citationRole of diet and exercise in aging, Alzheimer’s disease, and other chronic diseases
Khemka, S., Reddy, A., Garcia, R. I., Jacobs, M., Reddy, R. P., Roghani, A. K., Pattoor, V., Basu, T., Sehar, U., & Reddy, P. H. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102091 · Cited by 88
Wang, H., Wang, L., Hu, F., Wang, P., Xie, Y., Li, F., & Guo, B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01643-0 · Cited by 88
“The role of autophagy in cardiac pathogenesis has been reported inconsistently among different types of DM [19, 21, 46, 47].”
BackgroundLiu, H., Sridhar, V. S., Boulet, J., Dharia, A., Khan, A. A., Lawler, P. R., & Cherney, D. Z. I. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154918 · Cited by 90
Hyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure
Packer, M. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.030 · Cited by 93
Self-citationImmunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging
Schönberger, E., Mihaljević, V., Steiner, K., Šarić, S., Kurevija, T., Majnarić, L. T., Bilić-Čurčić, I., & Canecki-Varžić, S. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20176671 · Cited by 93
“The AMPK molecule plays a vital role in the regulation of bioenergy metabolism and is pivotal in our understanding of diabetes mellitus and other metabolic disorders [48].”
BackgroundSGLT2 inhibitors and lower limb complications: an updated meta‐analysis
Lin, C., Zhu, X., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01276-9 · Cited by 91
“Moreover, studies showed that cardiovascular and renal benefits from SGLT2i treatment might be in part mediated by a state of fasting mimicry via several molecular mechanisms [26] and the regulation of autonomic nervous system [27].”
BackgroundCardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Davies, M. J., Drexel, H., Jornayvaz, F. R., Pataky, Z., Seferovic, P. M., & Wanner, C. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01575-9 · Cited by 83
“Cardio- and reno-protective effects are unlikely to be solely explained by the mechanisms used by these drugs to lower blood glucose levels, as the same effects are not seen with drugs that have stronger antihyperglycaemic actions [111], and were not dependent upon the degree of HbA1c reduction [113–115].”
BackgroundRajpal, A., & Ismail‐Beigi, F. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14080 · Cited by 70
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Kim, H., Biessels, G. J., Yu, M. H., Hong, N., Lee, Y., Lee, B., Kang, E. S., Soo, B., Lee, E. J., & Lee, M. (2024) · Neurology · doi:10.1212/wnl.0000000000209805 · Cited by 78
Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation
Zhou, Y., Tai, S., Zhang, N., Fu, L., & Wang, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115213 · Cited by 72
Janež, A., & Fioretto, P. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01104-z · Cited by 70
“This would include the induction of a fastinglike state [46] by SGLT2 inhibition.”
BackgroundTsigkou, V., Oikonomou, E. K., Anastasiou, A., Lampsas, S., Zakynthinos, G. Ε., Kalogeras, K. I., Katsioupa, M., Kapsali, M., Kourampi, I., Pesiridis, T., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054321 · Cited by 78
Redox signaling in heart failure and therapeutic implications
Weissman, D., & Maack, C. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.05.013 · Cited by 61
SGLT2 inhibitors: Beyond glycemic control
Hasan, I., Rashid, T., Jaikaransingh, V., Heilig, C., Abdel‐Rahman, E. M., & Awad, A. S. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100335 · Cited by 89
“In addition, SGLT2 inhibitors may decrease the inflammatory process by activating the SIRT1/AMPK pathway, reducing oxidative stress, and enhancing antioxidant activity [77].”
BackgroundVerma, S., Dhingra, N. K., Butler, J., Anker, S. D., Ferreira, J. P., Filippatos, G., Januzzi, J. L., Lam, C. S. P., Sattar, N. A., Peil, B., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00292-8 · Cited by 62
Self-citationTsai, W.-C., Hsu, S.-P., Chiu, Y.-L., Yang, J.-Y., Pai, M.-F., Ko, M.-J., Tu, Y.-K., Hung, K.-Y., Chien, K.-L., Peng, Y.-S., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060655 · Cited by 53
Chewcharat, A., Prasitlumkum, N., Thongprayoon, C., Bathini, T. J., Medaura, J. A., Vallabhajosyula, S., & Cheungpasitporn, W. (2020) · Medical Sciences · doi:10.3390/medsci8040047 · Cited by 62
“Furthermore, SGLT-2 inhibitors also showed antioxidative effects via activation of SIRT1/AMPK, suppression of Akt/mTOR signaling pathway [65].”
Moellmann, J., Mann, P. A., Kappel, B. A., Kahles, F., Klinkhammer, B. M., Boor, P., Kramann, R., Ghesquière, B., Lebherz, C., Marx, N., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14814 · Cited by 57
“sion to other energetic sources with increased availability of free fatty acids, ketone bodies and glucagon—mimicking a fasting-like state.(7,8,13) This change in systemic substrate availability shifts cardiac fuel utiliza-”
BackgroundInfluentialSodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling
Salah, H. M., Verma, S., Santos‐Gallego, C. G., Bhatt, A. S., Vaduganathan, M., Khan, M. S., Lópes, R. D., Alaref, S. J., McGuire, D. K., & Fudim, M. (2022) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-022-10220-5 · Cited by 54
“All of these factors are integral to autophagy, and their activation (as with SGLT2 inhibitors) can lead to upregulation of autophagy [70, 71].”
BackgroundSayour, A. A., Oláh, A., Ruppert, M., Barta, B. A., Horvath, E. M., Benke, K., Pólos, M., Hartyánszky, I. L., Merkely, B. P., & Radovits, T. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01141-1 · Cited by 47
Barbarawi, M., Al‐Abdouh, A., Barbarawi, O., Lakshman, H. G., kasasbeh, M. A., & Chen, K. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10083-z · Cited by 48
Chen, M. (2023) · Toxicology Research · doi:10.1093/toxres/tfad007 · Cited by 51
Fu, J., Xu, H., Wu, F., Tu, Q., Dong, X., Xie, H., & Cao, Z. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.07.048 · Cited by 45
Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin
Fontes‐Carvalho, R., Santos‐Ferreira, D., Raz, I., Marx, N., Ruschitzka, F. T., & Cosentino, F. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab034 · Cited by 50
The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis
Tsampasian, V., Baral, R., Chattopadhyay, R. K., Dębski, M., Joshi, S. S., Reinhold, J., Dweck, M. R., Garg, P., & Vassiliou, V. S. (2021) · Cardiology Research and Practice · doi:10.1155/2021/9927533 · Cited by 51
“As a result, there is activation of signaling pathways that involve important enzymes such as the sirtuin 1 (SIRT1) and the adenosine monophosphate-activated protein kinase (AMPK), both of which attenuate oxidative stress and inflammation and promote oxidation of fatty acids resulting in ketonaemia [29, 30].”
BackgroundIacobini, C., Vitale, M., Haxhi, J., Pesce, C. M., Pugliese, G., & Menini, S. (2022) · Antioxidants · doi:10.3390/antiox11112183 · Cited by 47
Autophagy and lysosomal dysfunction in diabetes and its complications
Arden, C., Park, S. H., Yasasilka, X. R., Lee, E. Y., & Lee, M. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.06.010 · Cited by 47
JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy
Gangat, N., Szuber, N., Alkhateeb, H. B., Al‐Kali, A., Pardanani, A. D., & Tefferi, A. (2021) · Blood · doi:10.1182/blood.2021013996 · Cited by 49
Avgerinos, K. I., Mullins, R. J., Vreones, M. P., Mustapić, M., Chen, Q., Melvin, D. L., Kapogiannis, D., & Egan, J. M. (2022) · Cells · doi:10.3390/cells11213372 · Cited by 42
“empagliflozin induces beneficial cellular responses regardless of presence or absence of hyperglycemia [2,4].”
BackgroundZisis, M., Chondrogianni, M. E., Ανδρουτσάκος, Θ., Rantos, I., Oikonomou, E. K., Chatzigeorgiou, A., & Kassi, E. N. (2025) · Biomolecules · doi:10.3390/biom15030324 · Cited by 48
“On the contrary, a meta-analysis of several small studies suggested an association of rosiglitazone with MI and an overall trend toward death from CV causes [199].”
Wicik, Z., Nowak, A., Jarosz-Popek, J., Wolska, M., Eyileten, C., Siller-Matula, J. M., von Lewinski, D., Sourij, H., Filipiak, K. J., & Postula, M. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.901340 · Cited by 46
Williams, D. M., Nawaz, A., & Evans, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00951-6 · Cited by 37
The potential anti-arrhythmic effect of SGLT2 inhibitors
Duan, H.-Y., Barajas-Martínez, H., Antzelevitch, C. N., & Hu, D. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02312-0 · Cited by 45
“SGLT2i stimulate autophagy to protect the heart and kidneys by inducing hypoxia and fasting-like transcriptional and metabolic changes, involving AMPK, SIRT1 and HIF activation and mTOR suppression [45, 121, 122].”
BackgroundLiu, H., Sridhar, V. S., Montemayor, D., Lovblom, L. E., Lytvyn, Y., Ye, H., Kim, J., Ali, M. T., Scarr, D., Lawler, P. R., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14489 · Cited by 36
“SGLT2 inhibition may improve mitochondrial function by activating AMPK/SIRT1/PGC-1alpha/FGF21 ‘starvation’ pathways, which promote mitochondrial biogenesis and disposal of dysfunctional mitochondria.(39,40) FGF21 has been previously shown in animal models to be required for SGLT2 inhibitor-mediated reduction in fat ma…”
BackgroundBenefits of SGLT2 inhibitors in arrhythmias
Gao, J., Xue, G., Zhan, G., Wang, X., Li, J., Yang, X., & Xia, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1011429 · Cited by 41
Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease
Solomon, J., Festa, M. C., Chatzizisis, Y. S., Samanta, R., Suri, R. S., & Mavrakanas, T. A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108330 · Cited by 37
Xiang, B., Zhao, X.-Y., & Zhou, X. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01266-x · Cited by 37
“The beneficial effects on the cardiovascular system are suggested to involve aspects of metabolism, hormones, and inflammation [142, 143] but this mechanism is not totally consistent with the "thrifty substrate" hypothesis.”
ResultIDRIS, I. R., Zhang, R., Mamza, J. B., Ford, M., Morris, T., Banerjee, A., & Khunti, K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14437 · Cited by 34
“While further studies need to characterize the mechanisms of the reported cardiorenal benefits, it is probable, however, that the beneficial effects arise from the interaction of several direct and indirect actions.25 However, it is unlikely that glucose lowering alone is responsible: other antidiabetic therapies that…”
BackgroundInfluentialÇınar, T., Şaylık, F., Çiçek, V., Pay, L., Khachatryan, A., Alejandro, J., Erdem, A., & Hayıroğlu, M. İ. (2024) · Kardiologia Polska · doi:10.33963/v.phj.100199 · Cited by 36
Range of adiposity and cardiorenal syndrome
Pazos, F. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i8.322 · Cited by 35
Li, N., Zhou, G., Zheng, Y., Lv, D., Zhu, X., Wei, P., Zheng, M., Liu, S., Zhou, E., Sun, W., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0261986 · Cited by 33
Diallo, A., Carlos‐Bolumbu, M., & Galtier, F. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02154-4 · Cited by 38
“Natriuresis and osmotic diuresis with SGLT2 inhibitors or direct mediation effect via GLP-1 receptor activation on blood vessels and kidney with GLP-1 receptor agonists seem to be the potential mechanisms involved in reducing systolic BP [8–11].”
BackgroundAdvances in kidney disease: pathogenesis and therapeutic targets
Boima, V., Agyekum, A. B., Ganatra, K., Agyekum, F., Kwakyi, E. P. K., Inusah, J., Ametefe, E. N., & Adu, D. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1526090 · Cited by 43
Verma, S., Anker, S. D., Butler, J., & Bhatt, D. L. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13148 · Cited by 32
“of autophagy/mitophagy, and a stimulation of a fasting transcriptional paradigm.(44) SGLT2 inhibitors have also been shown to have favourable effects on left ventricular remod-”
BackgroundShyr, Z. A., Yan, Z., Ustione, A., Egan, E. M., & Remedi, M. S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0258054 · Cited by 36
“Thus, we may re-conceptualize the role of SGLT2i as organ-protective agents, including the endocrine pancreas in this study, by promoting adaptive cellular reprogramming of stressed cells for survival and function [59, 60].”
Tai, S., Zhou, Y., Fu, L., Ding, H., Zhou, Y., Yin, Z., Yang, R., Liu, Z., & Zhou, S. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19152 · Cited by 30
“It has been hypothesized that SGLT2i exert cardiovascular protective effects by mimicking a state of fasting [18,31], activating SIRT1 signaling as a response to starvation and cellular stress [32].”
BackgroundVerma, S., Mudaliar, S. R., & Greasley, P. J. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02652-5 · Cited by 30
Chambergo‐Michilot, D., Tauma‐Arrué, A., & Loli-Guevara, S. (2020) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2020.100690 · Cited by 33
“which changes the myocardial metabolism and raises antioxidant and anti-inflammatory effects [13,14].”
BackgroundPacker, M. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa344 · Cited by 27
“In experimental models, SGLT2 inhibitors act to reduce oxidative stress, ameliorate mitochondrial dysfunction, and attenuate proinflammatory pathways; potentially, all of these effects may be mediated by an effect of these drugs to promote autophagy.(5) This pattern of biological responses is consistent with an effect…”
BackgroundSelf-citationSGLT2 inhibitors attenuate endothelial to mesenchymal transition and cardiac fibroblast activation
Schmidt, K., Schmidt, A., Groß, S., Just, A., Pfanne, A., Fuchs, M., Jordan, M., Mohr, E., Pich, A., Fiedler, J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-65410-9 · Cited by 33
“Contrarily, other glucosuria promoting medications did not show such cardiovascular benefits 14 .”
BackgroundKumar, N., Kumar, B., Ashique, S., Yasmin, S., Venkatesan, K., Islam, A., Ghosh, S., Sahu, A., Bhui, U., & Ansari, M. Y. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112050 · Cited by 29
Afşar, B., & Afşar, R. E. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00442-4 · Cited by 32
Gunawan, P. Y., Gunawan, P. A., & Hariyanto, T. I. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01538-1 · Cited by 32
Packer, M., Lam, C. S. P., Butler, J., Zannad, F. M., Vaduganathan, M., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.052 · Cited by 32
“…have been shown to induce a state of global starvation mimicry, as evidenced by their effects to enhance intracellular nutrient deprivation signaling and autophagic flux across multiple organs, including the heart, 94,171,172 thereby mimicking the antiadipogenic actions of incretin-based drugs.”
Self-citationRenoprotective Effects of SGLT2 Inhibitors
Vallon, V. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.005 · Cited by 33
Maiorana, A., Tagliaferri, F., & Dionisi‐Vici, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1145111 · Cited by 28
SGLT2 inhibitors as a novel senotherapeutic approach
Yeşilyurt, Z. E., Qi, C., Wang, Y.-C., Simm, A., Deelen, L., Gasim, A. H. A., Lewis, F., & Ellison, G. M. (2025) · npj Aging · doi:10.1038/s41514-025-00227-y · Cited by 33
“SGLT2 inhibitors have been reported to reduce oxidative stress by activating SIRT1/AMPK signalling 78,151 .”
New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions
Chatzianagnostou, K., Gaggini, M., Suman, A. F., Simonini, L., & Vassalle, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116218 · Cited by 23
“…may improve cardiac function through action on glycosuria, as the effect of these drugs induces a state of ‘fasting mimicry’ which activates the enzymes with important anti-inflammatory effects within the heart, sirtuin 1 (SIRT1) and adenosine monophosphate-activated protein kinase (AMPK) [40].”
BackgroundCanagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK
Angé, M., Poortere, J. D., Ginion, A., Battault, S., Dechamps, M., Muccioli, G. G., Roumain, M., Morelle, J., Druart, S., Mathivet, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93156-1 · Cited by 25
Wong, C. K. H., Lau, K. T. K., Tang, E. H. M., Lee, C., Lee, C. Y. Y., Woo, Y. C., Au, I. C. H., Tan, K. C. B., & Lui, D. T. W. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01520-w · Cited by 21
“This brings about antioxidant and anti-inflammatory effects, and consequently cardio-protection [43].”
BackgroundEmerging role of antidiabetic drugs in cardiorenal protection
Fu, W.-J., Huo, J., Mao, Z., Pan, S.-K., Liu, D., Liu, Z., Wu, P., & Gao, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1349069 · Cited by 24
Williams, D. M., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00889-9 · Cited by 23
Ekanayake, P. S., & Mudaliar, S. R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14562 · Cited by 26
Zhou, R., Zhang, Z., Li, X., Duan, Q., Miao, Y., Zhang, T., Wang, M., Li, J., Zhang, W., Wang, L., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041668 · Cited by 21
“SGLT2 inhibitors, such as EMPA, protect the heart in T2DM by restoring autophagy through the activation of SIRT1/AMPK and suppression of the Akt/mTOR signaling pathway [90].”
InfluentialExpanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings
Cuttone, A., Cannavò, V., Abdullah, R. M. S., Fugazzotto, P., Arena, G., Brancati, S., Muscarà, A., Morace, C., Quartarone, C., Ruggeri, D., et al. (2025) · Cells · doi:10.3390/cells14090668 · Cited by 26
Rasalam, R. R., Atherton, J. J., Deed, G., Molloy‐Bland, M., Cohen, N. D., & Sindone, A. P. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13483 · Cited by 19
“The relative merits of the opposing ‘ketone’ and ‘dormancy state’ hypotheses, which have been the subject of intense debate, are better discussed in detail elsewhere.(86) Regardless, hypothesis-driven RCTs supporting any firm conclusions are lacking, and given the potential importance of this mechanism, the number pla…”
BackgroundLam-Chung, C. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1174692 · Cited by 20
The SGLT2 inhibitor empagliflozin attenuates atherosclerosis progression by inducing autophagy
Xu, H., Fu, J., Tu, Q., Shuai, Q. Y., Chen, Y., Wu, F., & Cao, Z. (2023) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-023-00974-0 · Cited by 20
“Furthermore, as a modulator of autophagy, AMPK has been found to play an important role, and SGLT2i have also been proposed to induce autophagy by activating the AMPK signaling pathway to exert cardiorenal-protective effects [25, 33], which was investigated in this study.”
Zhou, Y., Fu, L., Sun, J., Zhu, Z., Xing, Z., Zhou, S., Tai, S., & Wang, Y. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.698117 · Cited by 25
CREDENCE: Significant Victory for Diabetic Kidney Disease
Verma, A., Patel, A. B., Upadhyay, A., & Waikar, S. S. (2020) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.04.002 · Cited by 16
IFN-I signaling in cancer: the connection with dysregulated Insulin/IGF axis
Vella, V., Francesco, E. M. D., Bonavita, E., Lappano, R., & Belfiore, A. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.04.009 · Cited by 20
Amer, R. M., Eltokhy, A. K., El‐Esawy, R. O., Barakat, A. N., Basha, E., El‐Deeb, O. S., Aboalsoud, A., Elgharabawy, N. M., & Ismail, R. (2022) · Molecules · doi:10.3390/molecules27123659 · Cited by 20
“AMPK conserves mitochondrial function, thereby decreasing reactive oxygen species (ROS) formation and it attenuates the resultant proinflammatory and proapoptotic responses [23].”
BackgroundAl-Shamasi, A.-A., Elkaffash, R., Mohamed, M., Rayan, M., Al-Khater, D., Gadeau, A., Ahmed, R., Hasan, A., Eldassouki, H., Yalcin, H. C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312677 · Cited by 19
“It is more favorable to say that SGLT-2i works by mimicking the starvation state by stimulating the activity of AMPK and suppressing Akt/mTOR signaling to reduce oxidative stress, reduce inflammation, normalize mitochondrial function and structure, prevent IRI, and prevent the development of cardiomyopathy [158,159].”
BackgroundOngoing Clinical Trials in Aging-Related Tissue Fibrosis and New Findings Related to AhR Pathways
Yu, H., Feng, Z., Lin, W., Yang, K., Liu, R., Li, J., Liu, X., Pei, M., & Yang, H. (2022) · Aging and Disease · doi:10.14336/ad.2021.1105 · Cited by 17
“It seems that the benefits of SGLT2 inhibitors are independent of the glucose-lowering effects, and their renal protective effects may persist in CKD patients caused by factors other than type 2 diabetes [137, 138].”
BackgroundOstrominski, J. W., & Vaduganathan, M. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.04.035 · Cited by 21
Metadata
- Authors
- Packer, M.
- Affiliations
- Baylor University Medical Center (US)
- Corresponding author
- Packer, Milton
- ORCID
- Packer, Milton
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-02-11
- Volume
- 43
- Issue
- 3
- Pages
- 508-511
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3008610985
- Semantic Scholar
- 18ef104bcf8e540a8930b852692198f550512f79
- Cited by
- 247
- References
- 52
- Citations by year
- 2026: 24 · 2025: 31 · 2024: 29 · 2023: 37 · 2022: 33 · 2021: 71 · 2020: 22
- FWCI
- 30.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- SGLT2 inhibitors, cardiorenal benefits, cellular reprogramming, ketogenesis, ketone bodies, heart failure hospitalization, end-stage renal disease, type 2 diabetes, energy metabolism
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Fasting, Humans, Hypoglycemic Agents, Sodium-Glucose Transporter 2, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.